Effect of pramlintide on symptom, catecholamine, and glucagon responses to hypoglycemia in healthy subjects

What Was Tested

The paper reports a study of Glucagon and Amylin (Islet Amyloid Polypeptide), published as a randomized controlled trial.

Pramlintide is an analog of the human glucoregulatory hormone amylin.

To further test the effect of pramlintide on symptom, catecholamine, and glucagon responses, a 3-step hypoglycemic clamp was investigated in healthy volunteers.

Who Took Part

According to the abstract, 18 subjects were involved.

The age groups tagged for this paper are teenagers and adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

Because people in this Glucagon study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the subjects and researchers unaware of who received Glucagon.

The comparison arm used a placebo, so changes seen with Glucagon could be set against what happens without it.

Each person switched between Glucagon and the comparison at some point, usually with a gap in between.

At the end of each 60-minute clamp step, autonomic (sweating, palpitations, hunger, etc) and neuroglycopenic (confusion, headache, odd behavior, etc) symptoms were assessed using a validated visual analog scale questionnaire.

What Was Measured

To further test the effect of pramlintide on symptom, catecholamine, and glucagon responses, a 3-step hypoglycemic clamp was investigated in healthy volunteers.

Topics PubMed links to this paper include Amyloid, Autonomic Nervous System, Blood Glucose, Body Mass Index, Catecholamines, Glucagon and Glucose Clamp Technique.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glucagon and Amylin (Islet Amyloid Polypeptide) in 18 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2004 (Metabolism: clinical and experimental), a journal based in United States.

More context: the Glucagon compound page and the Amylin (Islet Amyloid Polypeptide) compound page, all human trials.